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ABSTRACT
Purpose of the study: to determine the efficacy, adverse effects and safety of a new Iranian 
generic product of  deferasirox (Osveral®) in Iranian transfusion  dependent major thalassemic 
(TD-MT) patients.
Methods:  In  9  main  thalassemia  treatment  centers,  all  of  TD-MT  patients  (aged  ≥2  yrs) 
with serum ferritin (SF) levels≥1000 ng/ml, or >100 ml/kg of RBC transfusion ,who could 
not tolerate parental iron chelating were recruited regardless of their previous iron chelation 
therapy. Periodical clinical and laboratory evaluations were conducted for  adverse effects 
(AEs). Primary efficacy end point was Mean of  Relative Change of Serum Ferritin (MRC-SF) 
from the baseline level during one year. Analysis of variance (ANOVA), t test, chi-square or 
Fisher exact test were used for statistic analysis appropriately (P values <0.05 were considered 
as statistical significant).
Results:  In  407  cases  the  male/female  ratio  was  0.98.  Mean  age  was  11.5±7.4  (2-58) 
years. The mean of initiating dose of Osveral® and mean usage dose during the study was                    
23.5±4.9 mg/kg and 24.9 ± 4.9 mg/kg respectively. MRC-SF was -11.44% ±38.92 and it 
showed significant decline in SF (P value<0.001) one hundred and forty eight patients out of 
407 patients experienced at least one. AE, the most common of them were transient increase 
in  serum creatinin (97;24.1%) and > 5 time increase in transaminases (24;5.89%).The causes 
of discontinuation of treatment were non-satisfactory treatment ( 24; 5.8%), poor or non-
compliance of patients (21;5.1%), and adverse effects (13; 3.1%) .
Conclusion: A detailed comparison with similar studies on deferasirox (Exjade®) shows a 
promising efficacy and safety for its Iranian generic product (Osveral ®).
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240INTRODUCTION
Comparatively iron overload  is a more serious and 
lethal  consequence  of  chronic  blood  transfusion 
than blood-borne infection. A unit of packed RBC 
contains 250-300mg iron (1 mg/ml).  Therefore, 
patients  receiving  more  than  100  units  of  RBC 
usually  develop  hemosiderosis.  Due  to  lack  of 
mechanisms  for  enhancing  iron  excretion,  iron 
accumulates  in  chronically  transfused  patients, 
ferritin  levels  rise,  followed  by  early  endocrine 
dysfunction  (glucose  intolerance  and  delayed 
puberty) which will ultimately lead to cirrhosis and 
cardiomyopathy (1). Liver biopsy in these pateints 
shows  both  parenchymal  and  reticuloendothelial 
iron.  Cardiac  toxicity  is  often  started  with 
early  development  of  pericarditis,  followed  by 
dysrhythmia  and  pump  failure  presaging  death 
within few years (2). 
The decision to start long-term transfusion support 
should  also  prompt  one  to  institute  therapy  with 
iron-chelating agents. Deferoxamine (DFO) is a well 
known parenteral iron chelator which has been in 
use for more than four decades. Despite occasional 
occurance of cataracts, deafness, growth arrest and 
local skin reactions, including urticaria, DFO is a 
relatively  nontoxic  drug  (3,4).  However,  despite 
DFO’s wide availability, some patients are unable to 
comply sufficiently with prescribed treatment due to 
side effects of variable severity, and the unpleasant 
and  cumbersome  nature  of  effective  chelating 
regimens, which prolonged and daily subcutaneous 
or  intravenous  DFO  administration  is  required 
(5). Therefore, in the absence of regular use of the 
chelator, iron steadily accumulates and may cause 
death due to iron-induced cardiac disease (6).
Deferiprone (DFP) was the first orally active iron 
chelator  which  was  initially  marketed  in  India  in 
1995 and subsequently in Europe in 1999 for patients 
whom treatment with DFO was inadequate. Studies 
have  demonstrated  its  efficacy,  and  especially 
support a potential cardio protective role of DFP in 
patients is mostly dependent on transfusion (7-9). 
Although  agranulocytosis  has  been  mentioned  as 
the most serious side effects of DFP, more common 
and  problematic  side  effects  are  gastrointestinal 
symptoms (e.g., nausea, vomiting, gastric discomfort 
and arthralgia) (10). Interestingly, poor compliance 
with Deferiprone has been reported due to patient’s 
negligence  to  take  the  drug  3  times  daily  for  a 
prolonged period which has led to non-satisfactory 
response to treatment (11).
Deferasirox    has  shown  promise  in  more  than  45 
registered clinical trials and other studies since 2003 
(12). It was originally marketed by Novartis under 
brand name of Exjade® (13). Single daily doses of 
10 up to 40  mg/kg deferasirox has shown to produce 
reductions  in  liver  iron  concentration  comparable 
to deferoxamine in chronically transfused adult and 
pediatric patients in many clinical studies . Deferasirox 
is generally well tolerated in adults, adolescents, and 
children as young as 2 years of age (13-16). 
Osveral®  is  a  brand  name  for  Deferasirox 
manufactured by Osvah, the Iranian Pharmaceutical 
Company  (17).  Osveral  received  its  marketing 
authorization  through  National  Food  and  Drug 
Department of Iran Ministry of Health (18) and is 
already on the list of drugs reimbursed by national 
health insurance scheme.
Despite presence of numerous studies conducted 
on efficacy and safety of Exjade®, it was deceided 
that safety and effciacy of Osvearl® to be evaluated 
in Iranian patients due to the possible genetical and 
environmental differences which might underline 
disease , theraputic behavior, diet , drug acceptence 
and complexity in pharmacokinetics of oral drugs. 
Therefore, a multicentral clinical trial was proposed 
and conducted to assess the efficacy and safety of 
a 52-weeks treatment with Osveral® in transfusion 
dependent  thalasemic  patients  with  evidence  of 
transfusion induced iron overload.
METHODS 
All  of  the  transfusion-dependent  major  thalassemic 
patients (aged  2 yrs) in 9 main treatment centers in 
Iran,  with  serum  ferritin  (SF)  levels    1000  ng/ml, 
or  with  a  history  of  multiple  transfusions  (>10 
transfusions  or  >100  ml/kg  of  RBCs)  who  could 
not tolerate parentral iron chelating , after acquiring 
primary clinical and lab examaminations according 
to the specified protocol, regardless of their previous 
iron  chelation  therapy  were  recruited  with  the 
observance  of  inclusion  and  exclusion  criteria 
(Tables  1  and  2).  Despite  presence  of  previous 
marketing authorization of Osveral® in the Iranian 
market, each patient was comprehensively informed 
about the study and also their rights to withdraw 
from the study whenever they wished.
Routine  laboratory  examinations  were  performed 
for each patient according to the specified protocols. 
Patient follow-up was performed in accordance with 
the therapeutic monitoring. Tablets were advised to 
be dispersed in a non-metallic glass of water (apple 
or orange juice if patient could not tolerate) until a 
fine suspension was obtained and it was taken on an 
empty stomach 30 min before a meal. 
According to wide alternation in serum ferritin level 
in different clinical situations, in this study primary 
efficacy end-point was the mean of monthly relative 
changes  in  serum  ferritin  concentration  during 
52  weeks  of  treatment  compared  with  baseline. 
Baseline  serum  ferritin  was  taken  as  the  average 
of the available, reliable and stable measurements 
within 35 days prior to the start of treatment. Serum 
ferritin was assessed at the beginning (days 1-35) 
and then every 4-8 weeks. 
Dose Adjustment 
According to the serum ferritin level and the mean 
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transfusional  iron  intake  (considering  the  volume 
and  rate  of  transfusion)  dose  adjustment  might 
become  necessary,  and  therefore  a  protocol  was 
recommended to physicians (Table 3). They were 
allowed to modify doses according to the clinical or 
paraclinical assessments such as alteration in serum 
creatinine, ALT and AST, and of course other AEs 
which might occur during the study.  Doses more 
than 30 mg/kg and up to 40 mg/kg were allowed in 
the middle of study according to FDA dose approval 
for Exjade® in 2008 (19).
Safety and Monitoring 
Safety  of  the  medicine  was  evaluated  through 
the  continuous  monitoring  and  recording  of AEs, 
as  well  as  thorough  monthly  clinical  visits  by  a 
trained  physician  during  the  study  and  routine 
laboratory assessments and physical examinations. 
The frequency of all observed AEs were reported as 
relative percent of the patients with defined AEs to 
total number of patients and according to this method 
the relative percentage of adverse effects could be 
categorized as below: 
Very Common: >10% 
Common: 1-10% 
Uncommon: 0.1-1% 
Rare: < 0.1% 
Physical  examination  and  laboratory  tests  before 
enrolment of patients in the study were: complete 
blood  count,  serum  creatinine,  BUN,  urine 
analysis,  serum  transaminases,  and  serum  ferritin 
level  (preferentially  two  times  before  initiation 
of  iron  chelating  therapy).  Monthly  visits  and 
monthly  or  at  least  bimonthly  laboratory  follow-
ups  profile  (according  to  available  facilities  and 
physician  judgment)  were  requested  during  the 
study.  Serologic  studies  for  HCV,  HBV  and  HIV 
infection  were  conducted  at  the  beginning  of  the 
study to exclude affected or suspicious cases from 
the study. Echocardiography or MRI T2*(for cases 
•
•
•
•
Patients above 2 years of age and older; No gender limitation 
Patients diagnosed to have major thalassemia 
Ferritin level above 1000 mg/dl or if the patient had more than 10 times of blood transfusion or the volume of transfused blood 
was above 100 cc/kg
Normal serum creatinine level 
No proteinuria in urine analysis 
Negative serologic tests for HCV, HBV and HIV 
Liver transaminases below 5-fold the normal upper limit 
Normal complete blood count (WBC>4500; AGC>1500; platelet>150000) 
No cardiac problem neither taking any cardiac drug 
No auditory or ophthalmologic problem 
Female patients who had reached menarche should be single or who are sexually active must use an effective method of 
contraception 
Not concomitant usage of hydroxyurea; interferon; or any investigational drugs
•
•
•
•
•
•
•
•
•
•
•
•
Table 1. Inclusion Criteria.
Pregnancy or  breast-feeding 
Progressive or persistent increase in the creatinine level :
Any cardiac, auditory or ophthalmic problem 
HCV, HBV or HIV infections 
Persistent liver transaminases above 5-fold of the normal level : 
Repeated unexplained cytopenia *(neutropenia < 1500/ml and thrombocytopenia<150000) and , unexplained agranulocytosis 
<500/ml ,
Severe nausea and vomiting (not controlled within 24 hours diagnosed by physician) 
Hypersensitivity to deferasirox 
Occurrence of any sever adverse effects regardless of  being drug related or not ,diagnosed by physician
Sever skin rashes (not controlled by corticosteroids diagnosed by physician ) 
Persistent or progressive proteinuria
Non-compliant or unreliable patients 
Any surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any 
drug. 
Falling serum ferritin consistently below 500 μg/l, consideration should be given to temporarily interruption therapy 
if serum ferritin increasing in 30% of baseline level and persists for    3 months despite of proper dose scaling Osveral® should 
be interrupted 
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
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>10  years  old),  and  assessment  of  auditory  and 
ophthalmic  system  at  the  beginning  of  therapy 
were  recommended  but  not  obligatory  for  all 
asymptomatic and clinically normal cases according 
to available facilities and the physician’s judgment. 
As a definition, if serum creatinine rose to more than 
33% of baseline serum creatinine two consecutive 
times, it was considered to be “rising creatinine”. If 
it decreased to its normal level after dose adjustment 
it was mentioned as temporary, and if it persisted 
or  progressed  it  was  categorized  as  “progressive 
creatinine rise”. More than 5 fold increase above the 
normal serum transaminase level was considered as 
severe liver dysfunction.
Statistical analyses
Quantitative  data  are  summarized  as  median  or 
mean ± standard deviation and categorical data as 
percentage.  Analysis  of  variance  (ANOVA)  and 
t  test  were  used  to  compare  continuous  variables 
between independent groups and repeated measure 
ANOVA  was  used  to  compare  Mean  of  Relative 
Changes of serum ferritin during the study period. 
Comparison of categorical variables was performed 
with chi-square or Fisher exact test appropriately. P-
values less than 0.05 were considered as statistically 
significant.
RESULTS
Out of 407 cases with completed data from 9 centers, 
202 patients (49.5%) were male and 205 patients 
(50.5%) were female. Mean age was 11.5 ± 7.4 (2-
58) years and mean weight was 27.7 ± 14.9 (8.5-75) 
kg. According to age groups, 93 patients (23%) were 
in the age group of 2-5 years, 206 patients (50.6%) in 
the age group 6-14 years, and 108 patients (26.4%) 
in the age group ≥17 years. 
Dosage and changes in serum ferritin
Mean baseline serum ferritin (SF) was 2210.4±1175.0 
(600-9076) ng/dl. Considering the baseline SF and 
recommended dose protocol, there were different 
starting  doses  of  Osveral®.  The  mean  initiating 
dose of Osveral® was 23.5±4.9 (10-35 mg/kg) and 
the mean dose of Osveral® prescribed during the 
course of the study was 24.9±4.9 (10-36.7) mg/kg. 
The  number  of  patients  in  the  centers  in  which 
their physicians did not accept to use doses more 
than 30 mg/kg (dose group A) was 191(46.9%) and 
those centers who used maximum dose of 40 mg/kg 
(dose group B) were 216(53.1%). The frequency of 
increase of dosage was significantly higher in dose 
group B in comparison to dose  group A (P-value 
0.0001). 
Mean  of    Relative  Changes  of  Serum  Ferritin 
(MRC-SF) was -11.4%  ± 38.9 ( +82.4% -197.4%) 
compared to baseline SF and it showed significant 
decline  in  SF  during  one  year  of  iron  chelating 
therapy with Osveral® (P value<0.001). The trend 
of MRC-SF (%) ± 2 Standard Errors  during the 
study is shown in figure 3. This index in dose group 
B patients (-13.6%± 42.1) was less than that in dose 
group A (-9%± 34.9). According to t test results there 
was no significant difference between dose group A 
and B in MRC-SF (P value = 0.24).  MRC-SF in 
patients older than 15 years age in their respective 
group was less than those in 6-14 and 2-5 years of 
age groups, but there was no significant difference 
among different age groups in MRC-SF (P value = 
0.14 and 0.26 respectively).
Safety
In  this  study  148  patients  out  of  407  patients 
experienced at least one form of AE.
All  AEs  without  any  further  investigation  for 
the  cause  and  effect  relationship  were  recorded                   
(Table 4).
The  median  (range)  of  time  span  between 
commencing  treatment  with  Osveral®  and 
occurrence of all AEs, creatinine rise, and severe 
increase in transaminases were 4.1(1-11), 3(1-10), 
and  4.7(2-11)  months,  respectively.  The  median 
(range) time span between starting and interruption 
or  discontinuation  of  treatment  was  6.1(1-11) 
months which was 4.6(1-11) months due to patients’ 
incompliance and 6.4(1-11) months due to severe 
AEs. The main causes of treatment withdrawal were 
non-satisfactory  response  in  24  (5.8%),  patients’ 
poor  or  non-compliance  21(5.1%),  and  AEs  in 
13(3.1%) cases.
Serum transaminases (ALT and AST) as indicator 
of  liver  function  were  elevated  more  than  5  fold 
of normal range in 24(5.89%) cases, which led to 
temporary  or  permanent  discontinuation  of  drug. 
Only in 4 patients the drug was aborted by physician 
due  to  persistence  or  recurrence  of  severe  liver 
function  test  (LFT)  disturbance.  There  was  no 
significant difference between dose groups A and B 
for occurrence of severe liver dysfunction (p-value 
= 0.62). Although the rate of severe disturbance of 
Table 3. Recommended dose adjustment Therapeutic Protocol.
                                          FERRITIN(mg/dl)
Rate of TX
500-1000  1000- 1500  1500-2000  2000-3000  3000-4000 >4000
Low (<2 units/month) or <7cc/kg/month 10 mg/kg  15 mg/kg  20 mg/kg  30 mg/kg  35 mg/kg 40 mg/kg
Medium(2-4U/month) or 7-14 cc/kg/month 10 mg/kg  20 mg/kg  25 mg/kg  30 mg/kg  35 mg/kg 40 mg/kg
High(>4 U/month) or  > 14 cc/kg/month 10 mg/kg  20 mg/kg  30 mg/kg  30 mg/kg  35 mg/kg 40 mg/kgEfficacy and safety of Iranian made Deferasirox (Osveral®) 244
LFTs in  ≥ 15 years age group was less than other 
age  groups,  no  statistically  significant  difference 
was observed (P value = 0.90) 
Rise in creatinine was observed in 97 out of 407 
patients (24.1%). It was significantly higher in dose 
group  B  in  comparison  to  dose  group A  patients                   
(p-value  =  0.001).  There  was  no  significant 
difference among age groups in the case of rising 
creatinine   (p-value = 0.66-0.56). Fifty eight out of 
407 (14.2%) cases had a rising creatinine not only 
greater than 33% of the baseline level but also more 
than upper limit of normal for age, 55 of them were 
children (<15 years old) and 3 of them were older 
than 15 years of age.
There was only one case of progressive creatinin rise 
that did not respond to dose reduction or transient 
drug interruption.
 
CONCLUSION
Although, phase 3 of clinical trial in evaluation of 
efficacy and safety of Exjade® had been preformed 
in  other  populations  (14-16),  this  study  on  the 
Osveral® the Iranian brand of deferasirox  has been 
designed  to  rule  out  the  effects  from  differences 
due  to  variations  in  genetic;  diet;  complexity  in 
absorption,  metabolism  and  the  pharmacokinetic 
characteristics of oral medications; and even cultures 
and  beliefs  regarding  the  imported  or  domestic 
products on clinical outcomes. In addition due to 
some published data about the diversity in efficacy 
and safety of some other drugs in Iranian thalassemic 
patients, there was a desire to evaluate efficacy and 
safety of this new generic drug  Osveral® in Iranian 
patients (11, 20). On the other hand opponents of 
conducting a clinical study referred to this fact that 
there is no need to do clinical trial in chemical non 
biologic generic drugs after physical, chemical and 
bioequivalence comparison tests with the main drug 
(21). Finally this study, which was first proposed by 
Management Center for Transplantation and Special 
Disease of Health deputy of Iran Ministry of Health, 
was conducted by members of the Iranian Pediatric 
Hematology  and  Oncology  Society  in  2008  and 
ended on May 2010.
Among all enrolled patients, 407 had the complete 
and  acceptable  data.  Lack  of  laboratory  data  at 
the  time  of  enrollment  and/or  during  the  study; 
disregarding treatment protocol; and short treatment 
period of less than one year of using their medicine 
were among the main reasons for patients to drop 
Figure 1. Mean of Relative Changes of SF (%) in patients during study comparing baseline SF.
SF= Serum Ferritin ; Month 0 = starting month;  rch_Month 1 (etc.)= relative change of SF (%) in first month comparing the baseline 
(etc.) ; 2SE = 2 Standard Errors of Mean
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out from the study.
In  comparison  to  another  multi  centric  non 
comparative  single  arm  study  on  237  thalassemic 
patients in the Middle East region, our study is further 
extended (15). Efficacy of Iron chelating agents were 
evaluated in many studies by measurement of dry 
liver iron concentration (LIC) and it was considered 
as a standard method for assessment of efficacy (14, 
15).
On the other hand, significant correlations between 
changes in serum ferritin and liver iron concentration 
(LIC) have been identified across various underlying 
anemia  (14,  22).  In  addition  the  measurement  of 
serum ferritin is convenient and inexpensive, and 
serial  measurements  provide  a  relatively  robust 
marker of iron burden. Accordingly current guidelines 
for assessment of iron burden and monitoring the 
efficacy of chelation therapy recommend the use of 
serum ferritin (23).   
Therefore due to limitations in LIC measurement 
in different centers and non compliance of patients 
and parents especially for liver biopsy in children, in 
the present study serum ferritin level instead of LIC 
measurement was purposed as an indicator of body 
iron burden.
It  seems  that  using  end  of  study  difference  in 
serum  ferritin  level  as  an  indicator  of  efficacy  is 
more suitable for long term studies because of less 
significant influence of frequent changes in serum 
ferritin  level  in  various  clinical  patterns  such  as 
infections, inflammations, and liver dysfunction (14-
16, 24). In this study MRC-SF during one year as 
main index and primary endpoint of efficacy show 
a  significant  decline  in  SF.  However,  considering 
the  increasing  MRC-SF  trend  in  the  lasted  4                         
months,  although  statistically  non-significant,  the 
study seems should be extended longer for a better 
evaluation of efficacy.
In  ESCALATOR  study  the  reduction  of  serum 
ferritin at the end of study toward base line ferritin 
in children (-166 ng/ml) was not as high as in adults 
(-846 ng/ml); and this difference was statistically 
significant. This significant difference was explained 
by higher iron overload due to huge blood transfusion 
in children in comparison to adults (15). Discrepancy 
between  results  of  this  study  and  ESCALATOR 
study in the case of age groups may be due to the 
effect of chronic iron overload on liver in adults who 
lose the sensitivity of their serum ferritin level as 
an indicator of iron burden. EPIC study showed a 
median absolute reduction of serum ferritin of -163 
ng/ml and -5.1% relative decline at the end of study 
but there was no comparison among different age 
groups (16).  
Negative  iron  balance  was  not  encountered  in 
many clinical trials with 20 mg/kg and less, (14) 
but in several investigations especially in phase III 
clinical trails - due lack of enough data available 
about the drug- the initial dosage (≤20 mg/kg) was 
administered which might finally affect the efficacy 
of  iron  chelating  therapy  (14).  For  example  in 
ESCALATOR study with initial median ferritin of 
3326 ng/ml, the starting dose was 20 mg/kg in all 
patients and the increase of dosage after 26 weeks 
was detected in 78% of patients (15,25). However 
in this study the starting dose and dosage adjustment 
was based on iron load (serum ferritin and/or LIC), 
iron intake, and the amount of transfusion. Therefore, 
the dosage increased and decreased in 44.7% and 
4.7%, of patients under study respectively.
Frequencies  of  causes  for  discontinuation  of 
treatment in this study compared with other studies 
are  included  in  table  5.  Although  there  was  no 
definite description in other studies, unsatisfactory 
Very common (>10%)
Transient Increase in  serum creatinin)  2 consecutive times)
> 33% of baseline level 
> 33% of baseline level AND  >ULN*  
96 (23.58%)
58 (14.2%)
Common (1-10%)
More than 5 times increase in transaminases:  24 (5.89%)
Skin rash 6 (1.47%)
loss of appetite  6 (1.47%)
Proteinuria 5 (1.22%)
Uncommon (<1%) / Rare: < 0.1%
Diarrhea 2 (0.49%)
Abdominal pain 2 (0.49%)
Blurred vision ;vomiting;
Epistaxis; headache; flank pain; progressive creatinin rise; thrombocytopenia; prolonged fever 
1 (0.24%)
*ULN= Upper Limit of Normal
Table 4. Categorized frequency of AEs; number (%) of patients with AEs.Efficacy and safety of Iranian made Deferasirox (Osveral®) 246
therapeutic effect (leads to drug discontinuation) are 
defined in our study as increase of serum ferritin more 
than 30% of baseline in more than 3 months despite 
dosage adjustment. Non compliance such as consent 
withdrawal and follow up discontinuation was mostly 
due  to  worriness  about  reported  complications  of 
deferasirox as a new medication which lead them to 
discontinue Osveral®  even with presentation of first 
symptoms of any adverse effect. 
Despite 153 reported adverse effects which led to 
drug discontinuation in EPIC study, there was no 
frequency  reports  about  the  type  of AEs  (16,28). 
However  in  the  present  study  among  13  patients 
whose AEs led to treatment termination the most 
prevalent complications by sequence are as below: 
proteinuria , 4 patients (31%); increase in serum liver 
transaminases more than 5 folds of normal  ,4 patients 
(31%);  severe  rash,  2  patients  (15.5%);creatinine 
increase, blurred vision and diarrhea, each one in 1 
patient (7.7%).
In  other  important  trials  the  prevalence  of  AEs 
were  76  and  85  percent,  however  when  those 
complications  defined  according  to  judgment  of 
physicians,  the  frequencies  were  between  44-50 
percent (15, 16).
In  their  studies,  adverse  effects  without  any 
investigation concerning the causes were reported 
in 152 patients (37.2%). 
The  most  prevalent  complications  in  this  study 
were  transient  increase  of  serum  creatinine  and 
more than 5 folds of normal increase in serum liver 
transaminases. Skin rashes and proteinuria were less 
prevalent  and  the  gastro-intestinal  complications 
were rare. 
The  low  rate  of  skin  rashes  and  gastro-intestinal 
complications    in  comparison  with  other  studies 
(Table 6) could be considered as mild complications 
which were not sensed by patients and not reported 
by  the  physician.  For  instance  from  6  patients 
reported with rash, 2 cases discontinued the drug 
despite proper management. This can also explain the 
diversity in overall rate of complications reported in 
this study (37.2%) in comparison with other studies 
(76-85%). Mildness of majority of skin rashes and 
gastro-intestinal  complications  of  Exjade®  are 
reported in official documents (30).
Diversity  in  statistics  about  transient  increase  of 
creatinine  comes  from  different  definitions  about 
this index. In some studies the increase of creatinine 
level  in  two  consecutive  measures;  was  not  only 
more than 33% of baseline, but also more than age 
specific limit especially in children; were considered 
as creatinine  rise (26,27,29). On the other hand, other 
studies rely on definition of creatinine rise more than 
33% of baseline or both of the definitions (14-16). 
With the first definition there were 58 cases (14.2%) 
with rising creatinine in our study, 55 of them were 
children and 3 were adults. On the other hand, this 
difference  may  be  related  to  physician  judgment 
in  allocating  complications  to  deferasirox  in  some 
studies. For example in ESCALATOR study, despite 
creatinine  rise  in  73  patients  (31%)  above  33% 
baseline  and  6  patients  (2.5%)  above  age  specific 
limits,  the  complications  which  were  allocated  to 
drug by investigator, were reported  just in 9 patients 
(3.8%)  and  there  was  not  any  drug  interruption                                     
due to complication despite one case of renal failure 
(15).
In this study increase in serum liver transaminases 
(both ALT and AST) more than 5 folds of normal 
limits  was  considered  as  liver  dysfunction,  while 
other studies relied on more than10 folds of normal 
limits of ALT. Therefore, it seems that the prevalence 
of liver dysfunction in this study was less than other 
studies. Absence of complications such as hearing 
disorders,  cataract,  and  cytopenia  which  were 
reported in other studies may be due to short duration 
of this study (1 year) compared with other studies.
In  conclusion,  the  results  of  the  Iranian  generic 
oral iron chelating agent (Osveral®) both in iron 
chelating  efficacy  and  safety  was  acceptable. But 
despite extended sample size in comparison to other 
studies, for more detailed results it is proposed that 
the study to be conducted for a more extended period 
of time with more patients. It seems that the patients 
satisfaction in different age groups would be the most 
required variable in future studies. Also it is advisable 
to include other methods of iron overload assessment 
liver tissue iron concentration and R2MRI in studies. 
Finally extension of ongoing generic medications in 
thalassemic patients emphasizes the importance of 
multi center clinical studies in Iran.
Current study EPIC (16,28) ESCALATOR(15,25) Cappellini et al (26) Piga et al (27)
Non-satisfactory treatment* 24 (5.8%) 12(1.3%) - 39 (8.3%) 8 (4.8%)
Poor or non-compliance of patients 21(5.1%) 29 (3.1%) 9 (3.6%) 52 (11%) 5 (3%)
Adverse events 13 (3.1%) 31(3.3%) 3 (1%) 50 (10.6%) 13 (7.7%)
Other(death, etc)  17 (1.8%) 3 (1%) 13 (2.8%) 4 (2.4%)
Total 58 (14.2%) 89 (9.5%) 12 (4.8%) 159 (33%) 31 (22.6%)
*Definition of this study : ferritin rise above 30% of baseline and not declining despite dosage adjustment for three consecutive 
months. There was not any definition in other studies.
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9 (3.8%)c 113 (38.2%)
Increased in serum Cr
>33% BL & > ULN
37 (3.9%)b
175 (10%)a 6 (2.5%)
34 (7.2%) 13 (7.7%)
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7 (0.6%) 13 (5.5%) 29 (6.1%) 11 (6.6%) 25 (8.4%)d
a.  Transfusion dependent patients
b.  major Thalasemia patients
c.  This complication specified to drug in 9 patients out of 73 due to physician judgment .there was not any other explanation.
d.  Definition of liver dysfunction in this study: ALT was 5 folds above normal
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